Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

147
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147
Tumor Immunotherapy01:27

Tumor Immunotherapy

533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanometabolism instructs hematopoietic stem cell specification.

The Journal of experimental medicine·2025
Same author

Veteran Characteristics Associated With Risk of 30-Day Inpatient Mental Health (IMH) Readmissions.

The Psychiatric quarterly·2025
Same author

Association between intensive community mental health recovery service initiation and psychiatric symptoms among veterans.

Psychological services·2025
Same author

Balanced Fluids Versus Normal Saline for Initial Fluid Resuscitation in Adults With Diabetic Ketoacidosis.

Journal of pharmacy practice·2024
Same author

Incorporating a peer-teaching, virtual, educational activity to teach newly approved medications in a senior seminar capstone course.

Currents in pharmacy teaching & learning·2023
Same author

Fludrocortisone Plus Hydrocortisone Versus Hydrocortisone Alone as Adjunctive Therapy in Septic Shock: A Retrospective Cohort Study.

The Annals of pharmacotherapy·2023
Same journal

Prescription drug prior authorization: costs to pharmacies and physicians.

The American journal of managed care·2026
Same journal

Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

The American journal of managed care·2026
Same journal

The societal costs of food insecurity: implications for managed care strategies.

The American journal of managed care·2026
Same journal

Availability of hospital financial assistance documents in non-English languages.

The American journal of managed care·2026
Same journal

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

The American journal of managed care·2026
Same journal

Social needs screening and supplemental benefits in Medicare Advantage.

The American journal of managed care·2026
See all related articles

Related Experiment Video

Updated: Jul 11, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Rituximab reference vs biosimilar utilization for oncology vs nononcology indications.

Bonnie A Labdi1, Rim A Elbeshbeshy, Michelle Winkler

  • 1MJH Life Sciences, 2 Clarke Dr, Ste 100, Cranbury, NJ 08512.

The American Journal of Managed Care
|November 10, 2023
PubMed
Summary
This summary is machine-generated.

Rituximab biosimilar use is increasing, particularly for oncology indications and in nonacademic settings. This study is the first to analyze the real-world utilization of three US rituximab biosimilars against the reference product.

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

636
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Experiment Videos

Last Updated: Jul 11, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

636
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Area of Science:

  • Pharmacoeconomics and Health Economics
  • Oncology and Hematology
  • Immunology and Rheumatology

Background:

  • Limited real-world data exist on rituximab biosimilar adoption across different indications compared to the reference product.
  • Existing studies primarily focus on oncology, leaving a gap in understanding non-oncology use patterns.
  • This study provides the first comprehensive analysis of the utilization of three US-approved rituximab biosimilars versus the reference rituximab.

Purpose of the Study:

  • To compare the real-world utilization of rituximab biosimilars (rituximab-abbs, rituximab-pvvr, rituximab-arrx) against the reference product.
  • To analyze adoption trends and patterns by indication (oncology vs. non-oncology), labeling (on-label vs. off-label), and healthcare setting (academic vs. nonacademic).

Main Methods:

  • A comparative analysis using deidentified real-world data of rituximab and its biosimilar dispensations from December 2018 to February 2022.
  • Data were extracted from Trisus Medication Compare, covering 28,025 encounters across 193 facilities.
  • Primary outcome: rituximab reference vs. biosimilar utilization, stratified by indication, labeling, and treatment setting.

Main Results:

  • Rituximab reference product showed higher initial dispensations for both oncology (78.4%) and non-oncology (88.3%) indications.
  • Biosimilar utilization significantly increased from 0.01% in 2019 to 59.9% in 2021, while reference product use decreased.
  • Higher biosimilar adoption was observed for on-label indications (67.7%) and in nonacademic settings (22.2%) compared to academic settings (10.3%).

Conclusions:

  • Real-world evidence demonstrates a growing adoption of rituximab biosimilars over time.
  • Biosimilar uptake is more pronounced for oncology indications and within nonacademic healthcare environments.
  • These findings highlight evolving treatment landscapes and the increasing integration of biosimilars in clinical practice.